771 related articles for article (PubMed ID: 23060426)
1. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
[TBL] [Abstract][Full Text] [Related]
2. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
[TBL] [Abstract][Full Text] [Related]
3. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
4. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
Akdim F; Visser ME; Tribble DL; Baker BF; Stroes ES; Yu R; Flaim JD; Su J; Stein EA; Kastelein JJ
Am J Cardiol; 2010 May; 105(10):1413-9. PubMed ID: 20451687
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.
Akdim F; Stroes ES; Sijbrands EJ; Tribble DL; Trip MD; Jukema JW; Flaim JD; Su J; Yu R; Baker BF; Wedel MK; Kastelein JJ
J Am Coll Cardiol; 2010 Apr; 55(15):1611-8. PubMed ID: 20378080
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
Reeskamp LF; Kastelein JJP; Moriarty PM; Duell PB; Catapano AL; Santos RD; Ballantyne CM
Atherosclerosis; 2019 Jan; 280():109-117. PubMed ID: 30500603
[TBL] [Abstract][Full Text] [Related]
7. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease.
Vogt A; Parhofer KG
Expert Opin Pharmacother; 2013 Apr; 14(6):691-7. PubMed ID: 23477485
[TBL] [Abstract][Full Text] [Related]
8. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.
McGowan MP; Tardif JC; Ceska R; Burgess LJ; Soran H; Gouni-Berthold I; Wagener G; Chasan-Taber S
PLoS One; 2012; 7(11):e49006. PubMed ID: 23152839
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
10. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.
Huijgen R; Abbink EJ; Bruckert E; Stalenhoef AF; Imholz BP; Durrington PN; Trip MD; Eriksson M; Visseren FL; Schaefer JR; Kastelein JJ;
Clin Ther; 2010 Apr; 32(4):615-25. PubMed ID: 20435231
[TBL] [Abstract][Full Text] [Related]
11. Mipomersen as a potential adjunctive therapy for hypercholesterolemia.
Patel N; Hegele RA
Expert Opin Pharmacother; 2010 Oct; 11(15):2569-72. PubMed ID: 20707601
[TBL] [Abstract][Full Text] [Related]
12. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
13. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.
Ricotta DN; Frishman W
Cardiol Rev; 2012; 20(2):90-5. PubMed ID: 22293857
[TBL] [Abstract][Full Text] [Related]
14. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.
Visser ME; Wagener G; Baker BF; Geary RS; Donovan JM; Beuers UH; Nederveen AJ; Verheij J; Trip MD; Basart DC; Kastelein JJ; Stroes ES
Eur Heart J; 2012 May; 33(9):1142-9. PubMed ID: 22507979
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.
Akdim F; Tribble DL; Flaim JD; Yu R; Su J; Geary RS; Baker BF; Fuhr R; Wedel MK; Kastelein JJ
Eur Heart J; 2011 Nov; 32(21):2650-9. PubMed ID: 21593041
[TBL] [Abstract][Full Text] [Related]
16. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
Toth PP
J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
[TBL] [Abstract][Full Text] [Related]
17. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
18. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
Bell DA; Hooper AJ; Watts GF; Burnett JR
Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
[TBL] [Abstract][Full Text] [Related]
19. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
Vishwanath R; Hemphill LC
J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
[TBL] [Abstract][Full Text] [Related]
20. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.
Santos RD; Raal FJ; Catapano AL; Witztum JL; Steinhagen-Thiessen E; Tsimikas S
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):689-99. PubMed ID: 25614280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
